Current status and future role of brain PET/MRI in clinical and research settings

Hybrid PET/MRI systematically offers a complementary combination of two modalities that has often proven itself superior to the single modality approach in the diagnostic work-up of many neurological and psychiatric diseases. Emerging PET tracers, technical advances in multiparametric MRI and obvious workflow advantages may lead to a significant improvement in the diagnosis of dementia disorders, neurooncological diseases, epilepsy and neurovascular diseases using PET/MRI. Moreover, simultaneous PET/MRI is well suited to complex studies of brain function in which fast fluctuations of brain signals (e.g. related to task processing or in response to pharmacological interventions) need to be monitored on multiple levels. Initial simultaneous studies have already demonstrated that these complementary measures of brain function can provide new insights into the functional and structural organization of the brain.

[1]  Lutz Tellmann,et al.  Comparison of cerebral blood flow acquired by simultaneous [15O]water positron emission tomography and arterial spin labeling magnetic resonance imaging , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  S. Nekolla,et al.  Hybrid PET/MR Imaging of the Heart: Potential, Initial Experiences, and Future Prospects , 2013, The Journal of Nuclear Medicine.

[3]  Thomas Beyer,et al.  Acquisition protocol considerations for combined PET/CT imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  G. Delso,et al.  Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR Scanner , 2011, The Journal of Nuclear Medicine.

[5]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[6]  H. Amthauer,et al.  [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Bernd J Pichler,et al.  On the Quantification Accuracy, Homogeneity, and Stability of Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging Systems , 2014, Investigative radiology.

[8]  Christine Bastin,et al.  Metabolic and structural connectivity within the default mode network relates to working memory performance in young healthy adults , 2013, NeuroImage.

[9]  Jochen Herms,et al.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  O. Sabri,et al.  Potential Pediatric Applications of PET/MR , 2014, The Journal of Nuclear Medicine.

[11]  Kevin T. Chen,et al.  Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners. , 2014, American journal of nuclear medicine and molecular imaging.

[12]  J. Tonn,et al.  Molecular imaging of gliomas with PET: opportunities and limitations. , 2011, Neuro-oncology.

[13]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[14]  N. Salamon,et al.  Fluorodeoxyglucose – Positron-Emission Tomography and MR Imaging Coregistration for Presurgical Evaluation of Medically Refractory Epilepsy , 2009 .

[15]  M. Sperling,et al.  Surgical outcome in PET‐positive, MRI‐negative patients with temporal lobe epilepsy , 2012, Epilepsia.

[16]  S. Warach,et al.  Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study , 2009, The Lancet Neurology.

[17]  Stephen Tyree,et al.  Predicting a multi-parametric probability map of active tumor extent using random forests , 2013, 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[18]  S. Goldman,et al.  POSITRON EMISSION TOMOGRAPHY‐GUIDED VOLUMETRIC RESECTION OF SUPRATENTORIAL HIGH‐GRADE GLIOMAS: A SURVIVAL ANALYSIS IN 66 CONSECUTIVE PATIENTS , 2009, Neurosurgery.

[19]  Olivier Dewitte,et al.  Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. , 2006, Journal of neurosurgery.

[20]  Gil Navon,et al.  Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI , 2013, Scientific Reports.

[21]  T. Neumann-Haefelin,et al.  Relationship between severity of MR perfusion deficit and DWI lesion evolution , 2001, Neurology.

[22]  Jean-Philippe Thiran,et al.  Structural connectomics in brain diseases , 2013, NeuroImage.

[23]  G. Fink,et al.  Erratum to: Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  R. Bammer,et al.  Optimal Tmax Threshold for Predicting Penumbral Tissue in Acute Stroke , 2009, Stroke.

[25]  R L Wahl,et al.  Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. , 1999, Radiology.

[26]  G. Moneta,et al.  Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke , 2009 .

[27]  John O. Prior,et al.  Combination of MRI and dynamic FET PET for initial glioma grading , 2014, Nuklearmedizin.

[28]  W. Heiss Radionuclide Imaging in Ischemic Stroke , 2014, The Journal of Nuclear Medicine.

[29]  F. Schick,et al.  Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales , 2013, Nature Medicine.

[30]  Yi Su,et al.  Noninvasive Estimation of the Arterial Input Function in Positron Emission Tomography Imaging of Cerebral Blood Flow , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  R. Sevick,et al.  How often are nonenhancing supratentorial gliomas malignant? A population study , 2002, Neurology.

[32]  W D Heiss,et al.  Tissue at Risk of Infarction Rescued by Early Reperfusion: A Positron Emission Tomography Study in Systemic Recombinant Tissue Plasminogen Activator Thrombolysis of Acute Stroke , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  L. Mosconi,et al.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  E. Krupinski,et al.  Quantitative Analysis of Hypoperfusion in Acute Stroke: Arterial Spin Labeling Versus Dynamic Susceptibility Contrast , 2013, Stroke.

[35]  Geoffrey A. Donnan,et al.  RAPID Automated Patient Selection for Reperfusion Therapy: A Pooled Analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study , 2011, Stroke.

[36]  R. Boellaard,et al.  Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8–12, 2013, Tubingen, Germany , 2014, Molecular Imaging and Biology.

[37]  Martina Bocchetta,et al.  Imaging markers for Alzheimer disease , 2013, Neurology.

[38]  T. Yen,et al.  Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  H. Quick,et al.  Magnetic Resonance–Based Attenuation Correction for PET/MR Hybrid Imaging Using Continuous Valued Attenuation Maps , 2013, Investigative radiology.

[40]  Ciprian Catana,et al.  Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe--feasibility study in rat model. , 2011, Radiology.

[41]  Guy B. Williams,et al.  In Vivo Quantitative Susceptibility Mapping (QSM) in Alzheimer's Disease , 2013, PloS one.

[42]  Norman E Bolus,et al.  PET/MRI: The Blended-Modality Choice of the Future?* , 2009, Journal of Nuclear Medicine Technology.

[43]  Richard E Carson,et al.  Cerebral blood flow with [15O]water PET studies using an image-derived input function and MR-defined carotid centerlines , 2013, Physics in medicine and biology.

[44]  B. Bender,et al.  Metabolic Mapping of Gliomas Using Hybrid MR-PET Imaging: Feasibility of the Method and Spatial Distribution of Metabolic Changes , 2013, Investigative radiology.

[45]  Josien P W Pluim,et al.  Arterial Spin Labeling Perfusion MRI at Multiple Delay Times: A Correlative Study with H215O Positron Emission Tomography in Patients with Symptomatic Carotid Artery Occlusion , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[46]  JanSobesky,et al.  Maps of Time to Maximum and Time to Peak for Mismatch Definition in Clinical Stroke Studies Validated With Positron Emission Tomography , 2010 .

[47]  Richard J. Davidson,et al.  Comparison of fMRI motion correction software tools , 2005, NeuroImage.

[48]  Glyn Johnson,et al.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. , 2004, AJNR. American journal of neuroradiology.

[49]  Osama Sabri,et al.  Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases , 2014, The Journal of Nuclear Medicine.

[50]  D. Head,et al.  Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly , 2010, Biological Psychiatry.

[51]  Ciprian Catana,et al.  MRI-Assisted PET Motion Correction for Neurologic Studies in an Integrated MR-PET Scanner , 2011, The Journal of Nuclear Medicine.

[52]  Ciprian Catana,et al.  Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI , 2013, Proceedings of the National Academy of Sciences.

[53]  Matthias Hofmann,et al.  Hybrid PET/MRI of Intracranial Masses: Initial Experiences and Comparison to PET/CT , 2010, The Journal of Nuclear Medicine.

[54]  K. Herholz,et al.  Methyl-l-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma , 2009, Journal of Nuclear Medicine.

[55]  S. Vandenberghe,et al.  MRI-Based Attenuation Correction for PET/MRI Using Ultrashort Echo Time Sequences , 2010, Journal of Nuclear Medicine.

[56]  Masoom A. Haider,et al.  Automated Prostate Cancer Localization with Multiparametric Magnetic Resonance Imaging , 2014 .

[57]  L. Mortelmans,et al.  [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. , 2006, AJNR. American journal of neuroradiology.

[58]  David T. Jones,et al.  Age-related changes in the default mode network are more advanced in Alzheimer disease , 2011, Neurology.

[59]  Morand Piert,et al.  Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[60]  Johan Nuyts,et al.  ML-reconstruction for TOF-PET with simultaneous estimation of the attenuation factors , 2014, 2012 IEEE Nuclear Science Symposium and Medical Imaging Conference Record (NSS/MIC).

[61]  J. Detre,et al.  Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[62]  S. Warach,et al.  Imaging of acute stroke , 2010, Nature Reviews Neurology.

[63]  K. Hoffmann,et al.  Definition of Primary and Secondary Glioblastoma—Letter , 2014, Clinical Cancer Research.

[64]  A. von Deimling,et al.  Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. , 2011, Neuro-oncology.

[65]  Fernando Boada,et al.  Adult brain tumor imaging: state of the art. , 2014, Seminars in roentgenology.

[66]  M. Mehta,et al.  Pseudoprogression after glioma therapy: a comprehensive review , 2013, Expert review of neurotherapeutics.

[67]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[68]  Ian Law,et al.  Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone , 2014, NeuroImage.

[69]  H. Duffau A new philosophy in surgery for diffuse low-grade glioma (DLGG): oncological and functional outcomes. , 2013, Neuro-Chirurgie.

[70]  P. Scheltens,et al.  EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia , 2012, European journal of neurology.

[71]  K. Hoffmann,et al.  Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors , 2014, Child's Nervous System.

[72]  G. Wagner,et al.  Multimodal functional and structural imaging investigations in psychosis research , 2012, European Archives of Psychiatry and Clinical Neuroscience.

[73]  George Jallo,et al.  The evaluation of FDG-PET imaging for epileptogenic focus localization in patients with MRI positive and MRI negative temporal lobe epilepsy , 2013, Neuroradiology.

[74]  G. Fink,et al.  Positron emission tomography in the differential diagnosis of organic dementias. , 1991, Journal of neural transmission. Supplementum.

[75]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[76]  Paul Edison,et al.  A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[77]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[78]  Bruce R. Rosen,et al.  Dynamic functional imaging of brain glucose utilization using fPET-FDG , 2014, NeuroImage.

[79]  Eric Guedj,et al.  Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project , 2013, The Journal of Nuclear Medicine.

[80]  Ciprian Catana,et al.  PET/MRI for Neurologic Applications , 2012, The Journal of Nuclear Medicine.

[81]  Scott Hamilton,et al.  Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study , 2006, Annals of neurology.

[82]  David W Jordan,et al.  PET/MR Imaging Consensus Paper: A Joint Paper by the Society of Nuclear Medicine and Molecular Imaging Technologist Section and the Section for Magnetic Resonance Technologists , 2013, The Journal of Nuclear Medicine Technology.

[83]  W. Jagust Time for tau. , 2014, Brain : a journal of neurology.

[84]  C. Kuhl,et al.  MRI-Based Attenuation Correction for Hybrid PET/MRI Systems: A 4-Class Tissue Segmentation Technique Using a Combined Ultrashort-Echo-Time/Dixon MRI Sequence , 2012, The Journal of Nuclear Medicine.

[85]  Karl-Josef Langen,et al.  O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.

[86]  Gaspar Delso,et al.  Systematic Comparison of the Performance of Integrated Whole-Body PET/MR Imaging to Conventional PET/CT for 18F-FDG Brain Imaging in Patients Examined for Suspected Dementia , 2014, The Journal of Nuclear Medicine.

[87]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[88]  Isabelle Salmon,et al.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[89]  D. Binns,et al.  The utility of a 3-dimensional, large-field-of-view, sodium iodide crystal--based PET scanner in the presurgical evaluation of partial epilepsy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[90]  Susan M. Chang,et al.  Age and the risk of anaplasia in magnetic resonance‐nonenhancing supratentorial cerebral tumors , 1997, Cancer.

[91]  C. Sorg,et al.  Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease , 2014, Alzheimer's & Dementia.

[92]  H. Sharma Multiparametric Imaging and MR Image Texture Analysis in Brain Tumors , 2014 .

[93]  Karsten Mueller,et al.  Combined Evaluation of FDG-PET and MRI Improves Detection and Differentiation of Dementia , 2011, PloS one.

[94]  G. Fink,et al.  Imaging of Non— or Very Subtle Contrast-Enhancing Malignant Gliomas with [11C]-Methionine Positron Emission Tomography , 2011, Molecular imaging.

[95]  Keith Muir,et al.  Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.

[96]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[97]  Karl J. Friston,et al.  Local Activity Determines Functional Connectivity in the Resting Human Brain: A Simultaneous FDG-PET/fMRI Study , 2014, The Journal of Neuroscience.

[98]  Tao Chan,et al.  Computerized Method for Automatic Evaluation of Lean Body Mass from PET/CT: Comparison with Predictive Equations , 2012, The Journal of Nuclear Medicine.

[99]  D. Townsend,et al.  Method for transforming CT images for attenuation correction in PET/CT imaging. , 2006, Medical physics.

[100]  P. Merlet,et al.  FDG-PET improves surgical outcome in negative MRI Taylor-type focal cortical dysplasias , 2010, Neurology.

[101]  Bernd J. Pichler,et al.  Assessment of rodent brain activity using combined [15O]H2O-PET and BOLD-fMRI , 2014, NeuroImage.

[102]  Swen Hesse,et al.  Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[103]  Johannes Schwarz,et al.  Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. , 2009, Archives of general psychiatry.

[104]  T. Narayanan,et al.  11C-Methionine PET for Grading and Prognostication in Gliomas: A Comparison Study with 18F-FDG PET and Contrast Enhancement on MRI , 2012, The Journal of Nuclear Medicine.

[105]  Habib Zaidi,et al.  Clinical Applications of Hybrid PET/MRI in Neuroimaging , 2013, Clinical nuclear medicine.

[106]  Gereon R. Fink,et al.  Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme , 2009, European Journal of Nuclear Medicine and Molecular Imaging.